Skip to content

Response to the EMA’s consultation on draft policy on access to clinical trial data

 

 

The European Medicines Agency (EMA) ran a consultation to discuss their proposed policy for access to clinical trial data for data submitted to the EMA from January 2014.

BPS noted support for the policy, suggested potential improvements and highlighted the wider issues regarding clinical trial data transparency which should be addressed.

Latest consultation responses

The British Pharmacological Society welcomes the opportunity to submit comments on the 'Regulation for Federal Financial Assistance' proposal, which…

The Good Clinical Trials Collaborative published new draft guidance for Randomized Controlled Trials (RCT). This guidance was developed in partnership…

 

 

In June 2021, the Department of Health & Social Care opened a call for evidence to inform their Women’s Health Strategy. In the…